---
layout: minimal-medicine
title: Paclitaxel (Protein Bound)
---

# Paclitaxel (Protein Bound)
### Generic Name
Paclitaxel (Protein Bound)

### Usage

Paclitaxel (protein bound) is a type of chemotherapy medication used to treat several types of cancer.  Its primary use is in treating breast cancer that has spread to other parts of the body (metastatic) and hasn't responded well to other chemotherapy combinations.  Specifically, it's indicated after failure of combination chemotherapy containing an anthracycline (unless clinically contraindicated) for metastatic disease or relapse within 6 months of adjuvant chemotherapy.

Importantly, this formulation is also used as a first-line treatment (meaning it's one of the first treatments used) for:

* **Locally advanced or metastatic non-small-cell lung cancer (NSCLC):**  It's used in combination with carboplatin, and sometimes other agents like pembrolizumab or atezolizumab, for patients who aren't suitable for surgery or radiation therapy.
* **Metastatic adenocarcinoma of the pancreas:**  In this case, it's given in combination with gemcitabine.

Beyond these primary uses, Paclitaxel (protein bound) is sometimes used off-label (meaning it's used for a purpose not officially approved by regulatory bodies) for other cancers such as biliary tract cancer, bladder cancer, cervical cancer, melanoma, and ovarian cancer.  However, the dosage and specific regimen will vary significantly based on the specific cancer type and its stage.  Always consult a healthcare professional for off-label use information.

### Dosage

The dosage of Paclitaxel (protein bound) is highly variable and depends on several factors including the specific cancer being treated, the patient's overall health (including liver and kidney function), and other medications they may be taking.  Dosage is usually calculated based on body surface area (BSA), which accounts for height and weight.  It is administered intravenously (IV).  The following are examples and *not* a complete list of all possible regimens:


**Breast Cancer (Metastatic):**

* Common regimen: 260 mg/m² every 3 weeks.
* Other regimens exist that use different dosages and schedules (e.g., 100-150 mg/m² on days 1, 8, and 15 of a 28-day cycle). These are often used in combination with other drugs.

**Non-small-cell Lung Cancer (Locally Advanced or Metastatic):**

* Common regimen: 100 mg/m² on days 1, 8, and 15 of a 21-day cycle, in combination with carboplatin, and sometimes other agents.

**Pancreatic Adenocarcinoma (Metastatic):**

* Common regimen: 125 mg/m² on days 1, 8, and 15 of a 28-day cycle, in combination with gemcitabine.

**Other Cancers:**  Off-label use in other cancers (such as biliary tract, bladder, cervical, melanoma, ovarian) necessitates a highly individualized dosing strategy. The regimen depends on many factors, and healthcare professionals determine the most appropriate course of treatment.

**Pediatric Use:** The safety and effectiveness of Paclitaxel (protein bound) in children have not been established.

**Important Note:** Paclitaxel (protein bound) is *not* interchangeable with other paclitaxel formulations.  Do not substitute.


### Side Effects

Paclitaxel (protein bound), like many chemotherapy drugs, can cause various side effects. The severity and frequency vary among individuals.

**Common Side Effects (>10%):**

* Nervous system: Fatigue, headache, peripheral neuropathy, depression
* Cardiovascular: Peripheral edema, ECG abnormalities (in patients with normal baseline)
* Gastrointestinal: Nausea, vomiting, diarrhea, constipation, decreased appetite, altered taste
* Dermatologic: Hair loss (alopecia), skin rash
* Hematologic: Low blood cell counts (anemia, neutropenia, thrombocytopenia)
* Hepatic: Increased liver enzyme levels (AST, ALT, ALP)
* Other:  Fever, infections, muscle aches, weakness

**Less Common, but Serious Side Effects:**

* Severe hypersensitivity reactions (including anaphylaxis)
* Severe neutropenia (very low white blood cell count) increasing risk of infection
* Severe thrombocytopenia (very low platelet count) increasing risk of bleeding
* Severe peripheral neuropathy (nerve damage)
* Cardiac problems (heart failure, arrhythmias)
* Pneumonitis (lung inflammation)
* Vision problems (including cystoid macular edema)
* Severe skin reactions


If you experience any side effects, especially serious ones, contact your healthcare provider immediately.


### How it Works

Paclitaxel (protein bound) is a type of drug called an antimicrotubule agent. It works by interacting with microtubules, which are essential components of cells involved in cell division.  Paclitaxel stabilizes these microtubules, preventing them from breaking down as they normally would during cell division. This disruption of the cell cycle ultimately leads to cell death, particularly in rapidly dividing cancer cells. The albumin-bound nanoparticle formulation is designed to improve the drug's delivery and reduce some side effects compared to other paclitaxel formulations.


### Precautions

* **Hypersensitivity:** Paclitaxel (protein bound) is contraindicated in patients with a history of severe hypersensitivity reactions to it or any of its components.
* **Bone Marrow Suppression:**  Paclitaxel (protein bound) can cause bone marrow suppression (decreased production of blood cells).  Regular blood tests are crucial to monitor this.
* **Cardiac Toxicity:**  It can affect the heart, particularly in patients with pre-existing heart conditions. Cardiac monitoring is often necessary.
* **Hepatic and Renal Impairment:** Dose adjustments may be needed for patients with liver or kidney problems.
* **Pregnancy and Breastfeeding:**  Paclitaxel (protein bound) is categorized as Pregnancy Category D, meaning it can harm a developing fetus. Effective contraception is essential during treatment and for a period afterward. It's also excreted in breast milk; breastfeeding should be avoided during treatment and for a period afterward.
* **Drug Interactions:**  It can interact with other drugs. Inform your doctor about all medications you are taking.
* **Extravasation:**  If the drug leaks out of the vein during infusion, it can cause serious tissue damage. Close monitoring of the infusion site is critical.

### FAQs

* **Q: How is Paclitaxel (protein bound) administered?** A: It is given intravenously (IV) over a specific timeframe, usually 30-40 minutes, depending on the treatment protocol.

* **Q: How long does treatment last?** A: Treatment duration varies depending on the type of cancer, the patient’s response to therapy, and the presence of side effects.  It can range from several cycles to longer durations.

* **Q: How is Paclitaxel (protein bound) stored?** A:  Always follow your pharmacist’s instructions on proper storage.

* **Q: Is Paclitaxel (protein bound) the same as other paclitaxel formulations?** A: No. It's a different formulation (albumin-bound nanoparticles) and is not interchangeable with other paclitaxel products.

* **Q: What should I do if I miss a dose?** A: Contact your doctor or healthcare provider immediately to discuss missed doses.  Do not attempt to adjust your dosage yourself.

* **Q: What should I do if I experience side effects?** A: Report any side effects, especially serious ones, to your healthcare provider immediately.  They can provide guidance on managing side effects and adjusting treatment as needed.

**Disclaimer:** This information is for educational purposes only and should not be considered medical advice. Always consult with a healthcare professional for any health concerns or before making any decisions related to your health or treatment.  They can provide personalized information based on your specific situation and medical history.
